company background image
ENZ

Enzo Biochem NYSE:ENZ Stock Report

Last Price

US$2.21

Market Cap

US$107.7m

7D

-2.2%

1Y

-37.2%

Updated

28 Sep, 2022

Data

Company Financials
ENZ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ENZ Stock Overview

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.

Enzo Biochem Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enzo Biochem
Historical stock prices
Current Share PriceUS$2.21
52 Week HighUS$4.15
52 Week LowUS$1.98
Beta0.85
1 Month Change-11.25%
3 Month Change6.76%
1 Year Change-37.22%
3 Year Change-37.22%
5 Year Change-78.95%
Change since IPO-19.75%

Recent News & Updates

Jun 27

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Board and Rabbani-affiliated President resigned. For these reasons, a company or asset sale may eventually materialise. The set-up appears to exist because of low liquidity and analyst coverage. Downside is limited by undervaluation and net cash position of ENZ.

Shareholder Returns

ENZUS HealthcareUS Market
7D-2.2%-0.6%-2.0%
1Y-37.2%7.9%-20.3%

Return vs Industry: ENZ underperformed the US Healthcare industry which returned 6.3% over the past year.

Return vs Market: ENZ underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is ENZ's price volatile compared to industry and market?
ENZ volatility
ENZ Average Weekly Movement9.3%
Healthcare Industry Average Movement8.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ENZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ENZ's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976483Hamid Erfanianhttps://www.enzo.com

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.

Enzo Biochem Fundamentals Summary

How do Enzo Biochem's earnings and revenue compare to its market cap?
ENZ fundamental statistics
Market CapUS$107.67m
Earnings (TTM)-US$6.56m
Revenue (TTM)US$111.60m

1.0x

P/S Ratio

-16.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ENZ income statement (TTM)
RevenueUS$111.60m
Cost of RevenueUS$64.16m
Gross ProfitUS$47.44m
Other ExpensesUS$54.00m
Earnings-US$6.56m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin42.51%
Net Profit Margin-5.88%
Debt/Equity Ratio7.0%

How did ENZ perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ENZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENZ?

Other financial metrics that can be useful for relative valuation.

ENZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA-12.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ENZ's PS Ratio compare to its peers?

ENZ PS Ratio vs Peers
The above table shows the PS ratio for ENZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14x
INFU InfuSystem Holdings
1.3x11.9%US$141.3m
TALK Talkspace
1.4x16.5%US$161.3m
CCM Concord Medical Services Holdings
1.2xn/aUS$73.8m
OHCS Optimus Healthcare Services
52.1xn/aUS$52.4m
ENZ Enzo Biochem
1xn/aUS$107.7m

Price-To-Sales vs Peers: ENZ is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (14x).


Price to Earnings Ratio vs Industry

How does ENZ's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: ENZ is good value based on its Price-To-Sales Ratio (1x) compared to the US Healthcare industry average (1.3x)


Price to Sales Ratio vs Fair Ratio

What is ENZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ENZ's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ENZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ENZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ENZ's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Enzo Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.8%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzo Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of ENZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Enzo Biochem competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Enzo Biochem performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-16.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ENZ is currently unprofitable.

Growing Profit Margin: ENZ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ENZ is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.

Accelerating Growth: Unable to compare ENZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENZ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (3.2%).


Return on Equity

High ROE: ENZ has a negative Return on Equity (-10.55%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Enzo Biochem's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ENZ's short term assets ($62.3M) exceed its short term liabilities ($24.7M).

Long Term Liabilities: ENZ's short term assets ($62.3M) exceed its long term liabilities ($17.0M).


Debt to Equity History and Analysis

Debt Level: ENZ has more cash than its total debt.

Reducing Debt: ENZ's debt to equity ratio has increased from 0.2% to 7% over the past 5 years.

Debt Coverage: ENZ's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if ENZ's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is Enzo Biochem current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Enzo Biochem Dividend Yield vs Market
How does Enzo Biochem dividend yield compare to the market?
SegmentDividend Yield
Company (Enzo Biochem)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Healthcare)1.4%
Analyst forecast in 3 Years (Enzo Biochem)n/a

Notable Dividend: Unable to evaluate ENZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ENZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENZ's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ENZ has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Hamid Erfanian (52 yo)

0.67yr

Tenure

Mr. Hamid Erfanian serves as Chief Executive Officer at Enzo Biochem, Inc. since November 8, 2021 and serves as Director since January 03, 2022. He served as Member of Executive Board at EUROIMMUN Medizini...


Leadership Team

Experienced Management: ENZ's management team is seasoned and experienced (5.6 years average tenure).


Board Members

Experienced Board: ENZ's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ENZ insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NYSE:ENZ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jul 22BuyUS$6,050Kara CannonIndividual2,500US$2.42
12 Jul 22BuyUS$28,375Bradley RadoffIndividual12,500US$2.27
05 Jul 22BuyUS$264,000Bradley RadoffIndividual120,000US$2.20
16 Jun 22BuyUS$275,500Bradley RadoffIndividual125,000US$2.21
15 Jun 22BuyUS$10,074Hamid ErfanianIndividual4,600US$2.19
14 Jun 22BuyUS$7,525David BenchIndividual3,500US$2.15
21 Mar 22SellUS$30,200Roumell Asset Management, LLCCompany10,000US$3.02
21 Dec 21BuyUS$2,484,891Bradley RadoffIndividual683,000US$3.64
21 Oct 21BuyUS$1,492,463Bradley RadoffIndividual414,501US$3.86
19 Oct 21BuyUS$302,700Radoff Family Foundation, Endowment ArmCompany90,599US$3.38
05 Oct 21BuyUS$2,465,421Bradley RadoffIndividual720,599US$3.50
01 Oct 21BuyUS$752,752Radoff Family Foundation, Endowment ArmCompany219,401US$3.50

Ownership Breakdown

What is the ownership structure of ENZ?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds8,192,07716.8%
Individual Insiders10,959,57022.5%
Institutions13,342,09827.4%
General Public16,226,70933.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 65.32% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.62%
Harbert Fund Advisors Inc.
5,175,913$11.4m0%9.84%
8.5%
Bradley Radoff
4,143,100$9.2m2.98%no data
6.7%
James Wolf
3,262,500$7.2m0%no data
6.19%
Renaissance Technologies LLC
3,016,164$6.7m0.17%0.01%
4.91%
Roumell Asset Management, LLC
2,390,211$5.3m-0.1%10.07%
3.83%
Elazar Rabbani
1,863,634$4.1m0%no data
3.63%
The Vanguard Group, Inc.
1,770,749$3.9m0%no data
3.29%
Dimensional Fund Advisors LP
1,602,375$3.5m0.49%no data
3.15%
Viex Capital Advisors, LLC
1,536,857$3.4m7.09%11.47%
3.14%
BlackRock, Inc.
1,530,255$3.4m-0.67%no data
2.65%
Barry Weiner
1,292,525$2.9m0%no data
1.97%
Fuller & Thaler Asset Management, Inc.
957,485$2.1m0.66%0.01%
1.15%
Potomac Capital Management Inc.
559,500$1.2m12.62%1.63%
0.88%
Radoff Family Foundation, Endowment Arm
430,000$950.3k0%18.15%
0.86%
Morgan Stanley, Investment Banking and Brokerage Investments
418,332$924.5k-14.31%no data
0.77%
Bridgeway Capital Management, LLC
375,700$830.3k0.08%0.02%
0.73%
Geode Capital Management, LLC
356,567$788.0k1.93%no data
0.56%
Hamid Erfanian
274,600$606.9k0%no data
0.51%
RBF Capital LLC
250,359$553.3k0%0.04%
0.38%
State Street Global Advisors, Inc.
185,639$410.3k-6.31%no data
0.23%
Northern Trust Global Investments
111,094$245.5k-0.39%no data
0.2%
Veritable LP
99,675$220.3k0%no data
0.18%
BNY Mellon Asset Management
85,283$188.5k-5.41%no data
0.15%
Corsair Capital Management, L.P.
75,026$165.8k0%0.06%
0.13%
Sns Financial Group, Llc, Asset Management Arm
62,500$138.1k0%0.02%

Company Information

Enzo Biochem, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Enzo Biochem, Inc.
  • Ticker: ENZ
  • Exchange: NYSE
  • Founded: 1976
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$107.672m
  • Shares outstanding: 48.72m
  • Website: https://www.enzo.com

Number of Employees


Location

  • Enzo Biochem, Inc.
  • 527 Madison Avenue
  • New York
  • New York
  • 10022
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENZNYSE (New York Stock Exchange)YesCommon StockUSUSDJun 1980
EZBDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1980
0IHVLSE (London Stock Exchange)YesCommon StockGBUSDJun 1980

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/04/30
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.